drugset / Trial / NCT02668393
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
Timeline
- Start
- 2016-03-07
- Primary completion
- 2019-11-27
- Completion
- 2019-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Nintedanib | Small molecule | — | — |